Valneva (NASDAQ:VALN) Stock Rating Reaffirmed by HC Wainwright

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $26.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 241.66% from the company’s current price.

Separately, Guggenheim lowered their target price on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Valneva Stock Down 2.7 %

Shares of NASDAQ VALN opened at $7.61 on Monday. The firm has a market cap of $529.96 million, a price-to-earnings ratio of -18.56 and a beta of 2.28. The company has a quick ratio of 2.22, a current ratio of 2.64 and a debt-to-equity ratio of 0.84. Valneva has a 52-week low of $6.58 and a 52-week high of $16.49. The business’s 50 day moving average is $7.99 and its two-hundred day moving average is $8.35.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.77 by $0.12. The business had revenue of $35.56 million during the quarter, compared to the consensus estimate of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. Research analysts predict that Valneva will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. increased its position in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.